Cullinan Oncology, Inc. Forecasted to Post Q1 2024 Earnings of ($1.00) Per Share (NASDAQ:CGEM)

Cullinan Oncology, Inc. (NASDAQ:CGEMFree Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for Cullinan Oncology in a research report issued on Monday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($1.00) per share for the quarter. The consensus estimate for Cullinan Oncology’s current full-year earnings is ($4.10) per share. Leerink Partnrs also issued estimates for Cullinan Oncology’s Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS and Q4 2024 earnings at ($1.06) EPS.

Cullinan Oncology (NASDAQ:CGEMGet Free Report) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.91).

Cullinan Oncology Stock Performance

Cullinan Oncology stock opened at $18.23 on Wednesday. The stock has a market cap of $779.88 million, a PE ratio of -4.87 and a beta of 0.24. Cullinan Oncology has a one year low of $7.64 and a one year high of $18.78. The stock has a fifty day moving average of $11.03 and a 200 day moving average of $10.13.

Institutional Trading of Cullinan Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CHI Advisors LLC increased its position in Cullinan Oncology by 1.9% in the second quarter. CHI Advisors LLC now owns 3,414,189 shares of the company’s stock worth $36,737,000 after buying an additional 64,729 shares in the last quarter. Vanguard Group Inc. increased its position in Cullinan Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,765,005 shares of the company’s stock worth $35,447,000 after buying an additional 19,486 shares in the last quarter. BlackRock Inc. grew its position in shares of Cullinan Oncology by 6.4% during the third quarter. BlackRock Inc. now owns 2,374,825 shares of the company’s stock worth $30,445,000 after purchasing an additional 143,098 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Cullinan Oncology by 195.8% during the second quarter. Franklin Resources Inc. now owns 2,334,086 shares of the company’s stock worth $25,115,000 after purchasing an additional 1,544,948 shares in the last quarter. Finally, Braidwell LP bought a new position in Cullinan Oncology during the second quarter valued at approximately $20,539,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Insider Activity at Cullinan Oncology

In related news, insider Corrine Savill sold 40,000 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $14.09, for a total transaction of $563,600.00. Following the completion of the sale, the insider now owns 165,990 shares in the company, valued at $2,338,799.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Cullinan Oncology news, insider Corrine Savill sold 40,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $14.09, for a total value of $563,600.00. Following the completion of the sale, the insider now owns 165,990 shares in the company, valued at $2,338,799.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Nadim Ahmed sold 4,272 shares of the company’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $9.24, for a total value of $39,473.28. Following the completion of the sale, the chief executive officer now owns 111,550 shares of the company’s stock, valued at approximately $1,030,722. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,514 shares of company stock worth $1,539,055. 8.82% of the stock is owned by insiders.

About Cullinan Oncology

(Get Free Report)

Cullinan Oncology, Inc a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer.

Read More

Earnings History and Estimates for Cullinan Oncology (NASDAQ:CGEM)

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.